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Targeted treatment of advanced NRAS-mutated melanoma
Peter Koelblinger and Reinhard Dummer
NRAS-mutations - most commonly in codon 
61 (Q61R or Q61K) - can be detected in around 20% 
of cutaneous melanomas and have been found more 
frequently in nodular primary melanomas and primary 
tumors from skin sites with chronic UV-exposure [1]. 
Also, patients with NRAS-mutated locally advanced or 
metastatic melanoma have been proposed to undergo 
a more aggressive disease course with an increased 
frequency of CNS involvement and decreased overall 
survival compared to wild-type tumors [2]. Despite 
a suggested trend towards an improved response to 
immunotherapies such as programmed death 1 (PD1)-
antibodies in NRAS-mutated melanoma patients [3], 
a substantial unmet medical need regarding targeted 
therapies remains in this patient subgroup. In contrast 
to the BRAF mutation routinely targeted clinically by 
effective BRAF inhibitor therapy, several attempts to 
directly target the mutant NRAS protein in melanoma have 
not even proven successful in vivo [4]. Hence, blockade of 
NRAS-mediated MAP-kinase pathway signaling through 
inhibition of the homologous kinases MEK 1 and 2 has 
evolved as the predominant strategy to target NRAS-
mutated melanoma. Due to promising results of a phase II 
trial with the MEK-inhibitor binimetinib which reported 
a 15% obective response rate (ORR) in a cohort of 117 
patients with NRAS-mutated melanoma [5], the phase III 
NEMO trial (NRAS melanoma and MEK inhibitor) was 
initiated.
Recently, the results of this randomized multicenter 
trial were reported in Lancet Oncology [6]. The trial 
compared binimetinib 45 mg BID with dacarbazine 1000 
mg/m2 intravenously Q3W in 402 patients with NRAS-
mutated locally advanced or metastatic melanoma, 
randomized in a 2:1 ratio (269 in the binimetinib and 
133 in the dacarbazine arm). The primary endpoint of 
progression-free survival (PFS) could be reached with 
binimetinib showing superior median PFS in comparison 
to dacarbazine (2.8 versus 1.5 months, hazard ratio 0.62; 
one-sided p-value <0.001). Median overall survival 
(OS) did not differ significantly being 11 months in the 
binimetinib and 10.1 months in the dacarbazine arm. The 
confirmed ORR of 15.2% was significantly higher in 
binimetinib-treated patients (6.8% with dacarbazine) and 
almost identical to earlier phase II results. The median 
duration of response with binimetinib was 6.9 months, 
which is similar to what has been reported for BRAF- 
and MEK-inhibitor monotherapy in BRAF-mutated 
melanoma. 
Taken together, binimetinib is the first kinase 
inhibitor to show clinical activity in a phase III trial in 
NRAS-mutated melanoma. However, despite statistical 
significance, the PFS improvement compared to 
chemotheraphy is modest, which has led to withdrawal of 
the new drug application for binimetinib at the FDA by the 
drug’s manufacturer in early 2017. 
Yet, a certain subgroup of patients with NRAS-
mutated melanoma may achieve increased benefit 
from binimetinib treatment, which is worth clinical 
consideration. The pre-specified subgroup of patients 
with prior immunotherapy treated with binimetinib in the 
NEMO trial (n = 57) showed an improved median PFS 
of 5.5 months. Furthermore, treatment responses in this 
subgroup seemed to be more durable, lasting for a median 
of 11 months. The response rate in immunotherapy treated 
patients, in turn, remained unchanged (15.8% versus 
15.2%). These observations point to a certain interaction 
between MEK-inhibitors and immunotherapy, with a 
positive outcome concerning MEK-inhibitor efficacy. We 
have recently summarized the various effects that MEK-
inhibitors can have on the interaction between tumors 
and the immune system and, in particular, how they can 
positively influence the T-cell repertoire in the tumor 
microenvironment [7]. Preclinical findings in this context 
are also supported by promising early results of a phase I 
clinical study with the MEK-inhibitor cobimetinib and the 
anti-PD-ligand 1-antibody atezolizumab in BRAF-mutant 
and wild-type melanoma [8]. 
Meanwhile, before the advent and availability of 
further clinical studies combining MEK-inhibitors and 
immunotherapy, we believe that in patients with NRAS-
mutated melanoma, binimetinib represents a new and 
valuable treatment option after failure of immunotherapy 
which is worth to be considered alternative to palliative 
chemotherapy or merely best supportive care, regardless 
of its current regulatory approval status. The efficacy 
of binimetinib treatment may also be improved through 
combination with other molecules such as CDK4/6, 
MDM2 or ERK inhibitors in the future.
Reinhard Dummer: Department of Dermatology, 
University Hospital of Zurich, Zurich, Switzerland
Correspondence to: Reinhard Dummer, email Reinhard.
dummer@usz.ch
Keywords: NRAS, melanoma, binimetinib, NEMO, MEK-inhib-
itor
              Editorial
Oncotarget84617www.impactjournals.com/oncotarget
Received: September 04, 2017
Published: September 29, 2017
REFERENCES
1. Lee JH, et al. Br J Dermatol. 2011; 164:776-784.
2. Jakob JA, et al. Cancer. 2012; 118:4014-4023.
3. Johnson DB, et al. Cancer Immunol Res. 2015; 3:288-295.
4. Posch C, et al. J Invest Dermatol. 2016; 136:1330-1336.
5. van Herpen CM, et al. ESMO Annual Meeting, Sep 2014, 
Madrid, Spain.
6. Dummer R, et al. Lancet Oncol. 2017; 18:435-445.
7. Dummer R, et al. Oncoimmunology. 2017; 6:e1335843.
8. Infante J, et al. Society for Melanoma Research Congress, 
Nov 2016, Boston, USA.
Copyright: Koelblinger et al. This is an open-access article 
distributed under the terms of the Creative Commons Attribution 
License 3.0 (CC BY 3.0), which permits unrestricted use, distri-
bution, and reproduction in any medium, provided the original 
author and source are credited.
